HOUSTON, Nov. 5, 2019 /PRNewswire/ — Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson...
80% of Methylated Patients and 75% of Unmethylated Patients Were Disease Progression-Free at 6 Months PLYMOUTH MEETING, Pa., Nov. 5, 2019 /PRNewswire/ — Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today positive interim results from Inovio’s Phase...
GAITHERSBURG, Md., Nov. 5, 2019 /PRNewswire/ — Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company developing cell and gene therapies for cancer and autoimmune diseases, today announced that it has initiated a Phase 1/2 clinical...
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the initiation of a Phase 1b clinical trial of mavorixafor (X4P-001) for the...
VANCOUVER, Nov. 5, 2019 /PRNewswire/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1...
MENLO PARK, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) — CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases and extend healthy lifespan, today announced the completion...
Email
Text